Revvity, Inc. (BIT:1RVTY)
Italy
· Delayed Price · Currency is EUR 87.22
+5.12 (6.24%)
At close: May 12, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 |
| Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Product Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Service Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Product Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Product Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Service Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Service Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) | 1.29B |
Log In |
Log In |
Log In |
Log In |
| Total Discovery & Analytical Solutions Revenue (Post-Q2 2022) Growth | -0.69% |
Log In |
Log In |
Log In |
Log In |
| Total Diagnostics Revenue (Pre-Q3 2022) | 1.48B |
Log In |
Log In |
Log In |
Log In |
| Total Diagnostics Revenue (Pre-Q3 2022) Growth | 3.73% |
Log In |
Log In |
Log In |
Log In |
| Total Product | 2.34B |
Log In |
Log In |
Log In |
Log In |
| Total Product Growth | -1.57% |
Log In |
Log In |
Log In |
Log In |
| Total Service | 434.73M |
Log In |
Log In |
Log In |
Log In |
| Total Service Growth | 23.09% |
Log In |
Log In |
Log In |
Log In |
| Life Sciences Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Life Sciences Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Applied Markets Revenue (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Applied Markets Revenue (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 |
| Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Pre-Q3 2022) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Post-Q2 2022) | 452.01M |
Log In |
Log In |
Log In |
Log In |
| Discovery & Analytical Solutions Operating Income (Post-Q2 2022) Growth | -1.92% |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Operating Income (Pre-Q3 2022) | 371.78M |
Log In |
Log In |
Log In |
Log In |
| Diagnostics Operating Income (Pre-Q3 2022) Growth | 15.21% |
Log In |
Log In |
Log In |
Log In |